February 13, 2025

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Therapeutic Designer Peptide to Combat Acute Heart Muscle Weakness

Researchers of the Heidelberg University, Heidelberg University Hospital (UKHD) and Heidelberg Institute for Theoretical Studies (HITS) have developed a synthetic peptide based on the natural protein S100A1, a nearly universal “fuel” for weakened hearts. The researchers combined computer-aided methods with lab studies to investigate the therapeutic effect of the so called S100A1ct peptide molecule. The results have been published in the journal “Circulation”.

Source: Heidelberg University Hospital

The “Molecular and Cellular Modeling” group led by Rebecca Wade was part of the project. The approach was to integrate experiments on heart muscle cells and animals and computational molecular modeling. “Our lab developed a customized computer-aided modeling pipeline for this project to model the molecular structure of the peptide and interactions with the predicted molecular effectors in the diseased heart cells”, Wade says. “The computational modeling guided the design of specific experiments to investigate the molecular mechanisms.”

The framework for the successful cooperation was provided by the Informatics for Life (I4L) Initiative, which was funded by the Klaus Tschira Foundation. The project received further financial support from the German Center for Cardiovascular Research with translational project funding from the Federal Ministry of Education and Research from the “Preclinical Confirmatory Studies” program.

For more information see the press release of the Heidelberg University Hospital:
https://www.klinikum.uni-heidelberg.de/newsroom/en/therapeutic-designer-peptide-to-combat-acute-heart-muscle-weakness/

Publication:

Kehr D, Ritterhoff J, Glaser M, et al. S100A1ct: A Synthetic Peptide Derived From S100A1 Protein Improves Cardiac Performance and Survival in Preclinical Heart Failure Models. Circulation. Published online November 21, 2024. doi:10.1161/CIRCULATIONAHA.123.066961

Scientific Contact:

Prof. Dr. Patrick Most 
Division of Molecular and Translational Cardiology
Department of Internal Medicine III 
Heidelberg University Hospital
Heidelberg Medical Faculty of Heidelberg University
patrick.most@med.uni-heidelberg.de

Prof. Dr. Rebecca Wade
Group Leader `Molecular and Cellular Modeling´
Heidelberg Institute for Theoretical Studies (HITS)
Center of Molecular Biology of Heidelberg University (ZMBH)
Heidelberg Medical Faculty of Heidelberg University

Press Contact:
Dr. Stefanie Seltmann
Head of Communications
Heidelberg University Hospital (UKHD)
presse@med.uni-heidelberg.de

Dr. Peter Saueressig
Head of Communications
Heidelberg Institute for Theoretical Studies (HITS)
comms@h-its.org

Our latest News

discover more
Cardiac Arrhythmias: New Defibrillator System Expands Treatment Options at UKHD

Cardiac Arrhythmias: New Defibrillator System Expands Treatment Options at UKHD

At Heidelberg University Hospital (UKHD), there is a new treatment option for certain patients with severe cardiac arrhythmias: an implantable defibrillator in which the electrode—unlike in conventional defibrillators—is placed outside the heart and blood vessels. This protects the blood vessels. In addition, the system can correct some arrhythmias using mild electrical impulses before an electric […]

The Individual Genetic Background Shapes the Evolution of Cancer

The Individual Genetic Background Shapes the Evolution of Cancer

Why do cancers develop differently in different people—even when they are exposed to the same risk factors? An international research group, including the German Cancer Research Center (DKFZ), has now demonstrated in mice that an organism’s genetic makeup significantly influences the course of cancer development. The findings, now published in Nature, provide new insights into […]

Cell Signaling Technology Announces ISO 13485 Certification

Cell Signaling Technology Announces ISO 13485 Certification

Certification enables increased support for partners and customers with industry-leading antibody reagents for commercial applications. Danvers, MA, USA, July 16, 2026–Cell Signaling Technology (CST), a life science discovery technology company and leading provider of antibodies, kits, and services, today announced that its Beverly, MA, US and Leiden, NL facilities have achieved ISO 13485:2016 certification for […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp